Dr. Garabedian is a faculty member in the Department of Population Medicine (DPM). She is a member of the Division of Health Policy and Insurance Research (HPI).
Dr. Garabedian’s research focuses on the robust evaluation of global and domestic health insurance reforms, insurer-led health system delivery reforms and pharmaceutical policies. She is also interested in the evaluation and development of analytic methods for health policy research, with a particular focus on observational data methods for comparative effectiveness research.
Dr. Garabedian received her PhD in Health Policy from Harvard University, with a specialization in evaluative science and statistics. She was a pre-doctoral Pharmaceutical Policy Research Fellow and a post-doctoral Pyle Fellow at DPM. Prior to Harvard, Dr. Garabedian worked as a research analyst at the Tufts Center for the Study of Drug Development. She has an MPH from Tufts and a BA from Boston University.
Garabedian LF, Chu P, Toh S, Zaslavsky A, Soumerai S. The Invalidity of the Most Common Instrumental Variable Analyses in Comparative Effectiveness Research. Annals of Internal Medicine. 2014; 161(2):131-138.
Garabedian LF, Ross-Degnan D, Ratanawijitrasin S, Stephens P, Wagner AK. Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study. BMJ Open. 2012; 2(6). Available at: http://bmjopen.bmj.com/content/2/6/e001686.full
Faden L, Vialle-Valentin C, Ross-Degnan D, Wagner A. Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence. Health Policy. 2011;100(2-3):134-143.